{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:34:11Z","timestamp":1793612051868,"version":"4.5.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007551","name":"Hallym University Medical Center","doi-asserted-by":"crossref","award":["Mighty Hallym 4.0 (MH 4.0)."],"award-info":[{"award-number":["Mighty Hallym 4.0 (MH 4.0)."]}],"id":[{"id":"10.13039\/501100007551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02208-9","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T12:56:29Z","timestamp":1752843389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Systemic strategies for osteosarcoma: advances and future directions"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-4883","authenticated-orcid":false,"given":"Vivek Kumar","family":"Morya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8445-2917","authenticated-orcid":false,"given":"Anuja Gajanan","family":"Magar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1656-185X","authenticated-orcid":false,"given":"Sin-Hye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-2977","authenticated-orcid":false,"given":"Kyu-Cheol","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2208_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.780264","volume":"11","author":"G Sheng","year":"2021","unstructured":"Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and metastasis. Front Oncol. 2021;11: 780264. https:\/\/doi.org\/10.3389\/fonc.2021.780264.","journal-title":"Front Oncol"},{"key":"2208_CR2","volume-title":"Osteosarcoma, updated 2023","author":"S Prater","year":"2024","unstructured":"Prater S, McKeon B. Osteosarcoma, updated 2023. Treasure Island: StatPearls; 2024."},{"key":"2208_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100372","volume":"29","author":"X Chang","year":"2021","unstructured":"Chang X, Ma Z, Zhu G, Lu Y, Yang J. New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma. J Bone Oncol. 2021;29: 100372. https:\/\/doi.org\/10.1016\/j.jbo.2021.100372.","journal-title":"J Bone Oncol"},{"key":"2208_CR4","doi-asserted-by":"publisher","first-page":"1117867","DOI":"10.3389\/fonc.2023.1117867","volume":"13","author":"X Du","year":"2023","unstructured":"Du X, Wei H, Zhang B, Wang B, Li Z, Pang LK, Zhao R, Yao W. Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities. Front Oncol. 2023;13:1117867. https:\/\/doi.org\/10.3389\/fonc.2023.1117867.","journal-title":"Front Oncol"},{"issue":"2","key":"2208_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.003.","journal-title":"Trends Cancer"},{"key":"2208_CR6","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.12688\/f1000research.9465.1","volume":"5","author":"SS Bielack","year":"2016","unstructured":"Bielack SS, Hecker-Nolting S, Blattmann C, Kager L. Advances in the management of osteosarcoma. F1000Research. 2016;5:2767. https:\/\/doi.org\/10.12688\/f1000research.9465.1.","journal-title":"F1000Research"},{"issue":"2","key":"2208_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40744-016-0046-y","volume":"3","author":"RA Durfee","year":"2016","unstructured":"Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther. 2016;3(2):221\u201343. https:\/\/doi.org\/10.1007\/s40744-016-0046-y.","journal-title":"Rheumatol Ther"},{"key":"2208_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100319","volume":"25","author":"E Papakonstantinou","year":"2020","unstructured":"Papakonstantinou E, Stamatopoulos A, Athanasiadis ID, Kenanidis E, Potoupnis M, Haidich AB, Tsiridis E. Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis. J Bone Oncol. 2020;25: 100319. https:\/\/doi.org\/10.1016\/j.jbo.2020.100319.","journal-title":"J Bone Oncol"},{"issue":"6","key":"2208_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00264-006-0192-x","volume":"30","author":"D Carrle","year":"2006","unstructured":"Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006;30(6):445\u201351. https:\/\/doi.org\/10.1007\/s00264-006-0192-x.","journal-title":"Int Orthop"},{"issue":"1","key":"2208_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13046-023-02850-7","volume":"42","author":"UK Soni","year":"2023","unstructured":"Soni UK, Jenny L, Hegde RS. IGF-1R targeting in cancer - does sub-cellular localization matter? J Exp Clin Cancer Res CR. 2023;42(1):273. https:\/\/doi.org\/10.1186\/s13046-023-02850-7.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"2208_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.830546","volume":"12","author":"Y Lu","year":"2022","unstructured":"Lu Y, Zhang J, Chen Y, Kang Y, Liao Z, He Y, Zhang C. Novel immunotherapies for osteosarcoma. Front Oncol. 2022;12: 830546. https:\/\/doi.org\/10.3389\/fonc.2022.830546.","journal-title":"Front Oncol"},{"key":"2208_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-030-51160-9_7","volume-title":"Sarcomas of bone and soft tissues in children and adolescents","author":"P Meyers","year":"2021","unstructured":"Meyers P. Osteosarcoma: history of therapy. In: Sarcomas of bone and soft tissues in children and adolescents. Springer International Publishing; 2021. p. 87\u201390."},{"issue":"3","key":"2208_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053083","volume":"12","author":"AD Hazewinkel","year":"2022","unstructured":"Hazewinkel AD, Lancia C, Anninga J, van de Sande M, Whelan J, Gelderblom H, Fiocco M. Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial. BMJ Open. 2022;12(3): e053083. https:\/\/doi.org\/10.1136\/bmjopen-2021-053083.","journal-title":"BMJ Open"},{"issue":"3","key":"2208_CR14","first-page":"301","volume":"61","author":"AC Poon","year":"2020","unstructured":"Poon AC, Matsuyama A, Mutsaers AJ. Recent and current clinical trials in canine appendicular osteosarcoma. Can Vet J La revue veterinaire canadienne. 2020;61(3):301\u20138.","journal-title":"Can Vet J La revue veterinaire canadienne"},{"issue":"15","key":"2208_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1080\/14656566.2021.1936499","volume":"22","author":"C Meazza","year":"2021","unstructured":"Meazza C, Asaftei SD. State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma. Expert Opin Pharmacother. 2021;22(15):1995\u20132006. https:\/\/doi.org\/10.1080\/14656566.2021.1936499.","journal-title":"Expert Opin Pharmacother"},{"key":"2208_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100362","volume":"28","author":"P M\u00fadry","year":"2021","unstructured":"M\u00fadry P, K\u00fdr M, Rohleder O, Mahdal M, Staniczkov\u00e1 Zambo I, Je\u017eov\u00e1 M, Tom\u00e1\u0161 T, \u0160t\u011brba J. Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy\u2014observational prospective single institution analysis. J Bone Oncol. 2021;28: 100362. https:\/\/doi.org\/10.1016\/j.jbo.2021.100362.","journal-title":"J Bone Oncol"},{"key":"2208_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-04843-7_1","volume":"804","author":"N Jaffe","year":"2014","unstructured":"Jaffe N. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol. 2014;804:1\u201330. https:\/\/doi.org\/10.1007\/978-3-319-04843-7_1.","journal-title":"Adv Exp Med Biol"},{"key":"2208_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-3-030-29676-6_38","volume-title":"Diagnosis of Musculoskeletal tumors and tumor-like conditions: clinical, radiological and histological correlations-the Rizzoli case archive","author":"S Ferrari","year":"2020","unstructured":"Ferrari S, Palmerini E. Chemotherapy of osteosarcoma. In: Diagnosis of Musculoskeletal tumors and tumor-like conditions: clinical, radiological and histological correlations-the Rizzoli case archive. Spinger; 2020. p. 217\u201321."},{"issue":"2","key":"2208_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-021-04371-6","volume":"89","author":"XZ Wen","year":"2022","unstructured":"Wen XZ, Pan QZ, Xu BS, Xiao W, Weng DS, Zhao JJ, Xu HR, Huang Z, Niu XH, Zhang X. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemother Pharmacol. 2022;89(2):209\u201315. https:\/\/doi.org\/10.1007\/s00280-021-04371-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2208_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-4615-3518-8_31","volume":"62","author":"MP Link","year":"1993","unstructured":"Link MP. The multi-institutional osteosarcoma study: an update. Cancer Treat Res. 1993;62:261\u20137. https:\/\/doi.org\/10.1007\/978-1-4615-3518-8_31.","journal-title":"Cancer Treat Res"},{"issue":"4","key":"2208_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.1991.9.4.600","volume":"9","author":"AM Goorin","year":"1991","unstructured":"Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991;9(4):600\u20135. https:\/\/doi.org\/10.1200\/JCO.1991.9.4.600.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2208_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-023-11024-9","volume":"23","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wu H, Xu G, Xu Y, Ma W, Li Z, Zhang J. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China. BMC Cancer. 2023;23(1):506. https:\/\/doi.org\/10.1186\/s12885-023-11024-9.","journal-title":"BMC Cancer"},{"issue":"1156","key":"2208_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bjr\/tqae040","volume":"97","author":"MS Hassan","year":"2024","unstructured":"Hassan MS, Ariyaratne S, Azzopardi C, Iyengar KP, Davies AM, Botchu R. The clinical significance of indeterminate pulmonary nodules in patients with primary bone sarcoma: a systematic review. Br J Radiol. 2024;97(1156):747\u201356. https:\/\/doi.org\/10.1093\/bjr\/tqae040.","journal-title":"Br J Radiol"},{"issue":"6","key":"2208_CR24","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/jcm10061213","volume":"10","author":"R Davison","year":"2021","unstructured":"Davison R, Hamati F, Kent P. What effect do pulmonary micronodules detected at presentation in patients with osteosarcoma have on 5-year overall survival? J Clin Med. 2021;10(6):1213. https:\/\/doi.org\/10.3390\/jcm10061213.","journal-title":"J Clin Med"},{"issue":"9","key":"2208_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27877","volume":"66","author":"J Bajpai","year":"2019","unstructured":"Bajpai J, Chandrasekharan A, Simha V, Mandal T, Shah K, Hingmare S, Rangarajan B, Shetty N, Vora T, Ghosh J, Rekhi B, Banavali S, Gupta S. Osteosarcoma journey over two decades in India: small steps, big changes. Pediatr Blood Cancer. 2019;66(9): e27877. https:\/\/doi.org\/10.1002\/pbc.27877.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2208_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1541-7786.MCR-18-0620","volume":"17","author":"SW Brady","year":"2019","unstructured":"Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau DA, Edmonson MN, Easton J, Alexandrov LB, Chen X, Mardis ER, Wilson RK, Downing JR, Pappo AS, Raphael BJ, Dyer MA, et al. The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment. Mol Cancer Res MCR. 2019;17(4):895\u2013906. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0620.","journal-title":"Mol Cancer Res MCR"},{"issue":"22","key":"2208_CR27","doi-asserted-by":"publisher","first-page":"12402","DOI":"10.3390\/ijms252212402","volume":"25","author":"M Roszkowska","year":"2024","unstructured":"Roszkowska M. Multilevel mechanisms of cancer drug resistance. Int J Mol Sci. 2024;25(22):12402. https:\/\/doi.org\/10.3390\/ijms252212402.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2208_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.52711\/2231-5691.2024.00030","volume":"14","author":"M Khatri","year":"2024","unstructured":"Khatri M, Dhar S, Ven P, Singh A. Understanding the pharmacological mechanisms of anticancer resistance: a multifaceted challenge in cancer treatment. Asian J Pharm Res. 2024;14(2):183\u20137.","journal-title":"Asian J Pharm Res"},{"key":"2208_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101901","volume":"42","author":"A Kar","year":"2024","unstructured":"Kar A, Agarwal S, Singh A, Bajaj A, Dasgupta U. Insights into molecular mechanisms of chemotherapy resistance in cancer. Transl Oncol. 2024;42: 101901. https:\/\/doi.org\/10.1016\/j.tranon.2024.101901.","journal-title":"Transl Oncol"},{"issue":"10","key":"2208_CR30","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1111\/cas.16295","volume":"115","author":"Z Li","year":"2024","unstructured":"Li Z, Lu H, Zhang Y, Lv J, Zhang Y, Xu T, et al. Blocking CXCR4\u2013CARM1\u2013YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis. Cancer Sci. 2024;115(10):3305\u201319. https:\/\/doi.org\/10.1111\/cas.16295.","journal-title":"Cancer Sci"},{"issue":"1","key":"2208_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-023-00685-8","volume":"24","author":"B Wu","year":"2023","unstructured":"Wu B, Li P, Qiu E, Chen J. Metformin alleviates adriamycin resistance of osteosarcoma by declining YY1 to inhibit MDR1 transcriptional activity. BMC Pharmacol Toxicol. 2023;24(1):50. https:\/\/doi.org\/10.1186\/s40360-023-00685-8.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"2208_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/1120009X.2023.2220583","volume":"36","author":"C Cao","year":"2024","unstructured":"Cao C, Pei Y, Yu H, Qi H. Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin. J Chemother. 2024;36(2):156\u201366. https:\/\/doi.org\/10.1080\/1120009X.2023.2220583.","journal-title":"J Chemother"},{"issue":"3","key":"2208_CR33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.20517\/cdr.2022.18","volume":"5","author":"DY Garcia-Ortega","year":"2022","unstructured":"Garcia-Ortega DY, Cabrera-Nieto SA, Caro-S\u00e1nchez HS, Cruz-Ramos M. An overview of resistance to chemotherapy in osteosarcoma and future perspectives. Cancer Drug Resist. 2022;5(3):762\u201393. https:\/\/doi.org\/10.20517\/cdr.2022.18.","journal-title":"Cancer Drug Resist"},{"key":"2208_CR34","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3332\/ecancer.2022.1363","volume":"16","author":"LF Ribeiro","year":"2022","unstructured":"Ribeiro LF, Campos FAB, Mello CA. Combination of ifosfamide and etoposide as a salvage regimen for previously treated soft tissue sarcomas: a retrospective single centre study. Ecancermedicalscience. 2022;16:1363. https:\/\/doi.org\/10.3332\/ecancer.2022.1363.","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"2208_CR35","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","volume":"24","author":"L Xie","year":"2019","unstructured":"Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist. 2019;24(7):e542\u201350. https:\/\/doi.org\/10.1634\/theoncologist.2018-0542.","journal-title":"Oncologist"},{"issue":"1","key":"2208_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3892\/ol.2021.12813","volume":"22","author":"L Xie","year":"2021","unstructured":"Xie L, Xu J, Sun X, Li X, Liu K, Liang X, Zhou Z, Zhuang H, Sun K, Wu Y, Gu J, Guo W. Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: a retrospective study in two centres. Oncol Lett. 2021;22(1):552. https:\/\/doi.org\/10.3892\/ol.2021.12813.","journal-title":"Oncol Lett"},{"issue":"1","key":"2208_CR37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1186\/s12885-024-12498-x","volume":"24","author":"E Tirtei","year":"2024","unstructured":"Tirtei E, Campello A, Sciannameo V, Asaftei SD, Meazza C, Sironi G, et al. Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study. BMC Cancer. 2024;24(1):747. https:\/\/doi.org\/10.1186\/s12885-024-12498-x.","journal-title":"BMC Cancer"},{"issue":"9","key":"2208_CR38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","volume":"22","author":"N Gaspar","year":"2021","unstructured":"Gaspar N, Venkatramani R, Hecker-Nolting S, Melcon SG, Locatelli F, Bautista F, Longhi A, Lervat C, Entz-Werle N, Casanova M, Aerts I, Strauss SJ, Thebaud E, Morland B, Nieto AC, Marec-Berard P, Gambart M, Rossig C, Okpara CE, He C, et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1\/2 study. Lancet Oncol. 2021;22(9):1312\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(21)00387-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2208_CR39","first-page":"299","volume":"6","author":"MB Aykan","year":"2022","unstructured":"Aykan MB, Yildiran GS, Akcan E, Acar R, Erturk I, Karadurmus N. Efficacy of ifosfamide, carboplatin and etoposide protocol in the treatment of relapsed or refractory bone and soft tissue sarcomas. Euras J Med Investig. 2022;6(3):299\u2013303.","journal-title":"Euras J Med Investig"},{"issue":"32","key":"2208_CR40","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2217\/fon-2021-0743","volume":"17","author":"N Gaspar","year":"2021","unstructured":"Gaspar N, Campbell-Hewson Q, Huang J, Okpara CE, Bautista F. OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed\/refractory osteosarcoma. Future Oncol (London, England). 2021;17(32):4249\u201361. https:\/\/doi.org\/10.2217\/fon-2021-0743.","journal-title":"Future Oncol (London, England)"},{"issue":"12","key":"2208_CR41","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164.","journal-title":"Oncologist"},{"issue":"2","key":"2208_CR42","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1002\/onco.13603","volume":"26","author":"WH Alsdorf","year":"2021","unstructured":"Alsdorf WH, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C. Standardized supportive care documentation improves safety of high-dose methotrexate treatment. Oncologist. 2021;26(2):e327\u201332. https:\/\/doi.org\/10.1002\/onco.13603.","journal-title":"Oncologist"},{"issue":"8","key":"2208_CR43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/jjco\/hyac059","volume":"52","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, Righi A, Kido A, Honoki K, Tanaka Y, Fujii H, Mavrogenis AF, Tanaka Y, Errani C. Effect of adjuvant chemotherapy on periosteal osteosarcoma: a systematic review. Jpn J Clin Oncol. 2022;52(8):896\u2013904. https:\/\/doi.org\/10.1093\/jjco\/hyac059.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"2208_CR44","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/jcm10061182","volume":"10","author":"R Rathore","year":"2021","unstructured":"Rathore R, Van Tine BA. Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies. J Clin Med. 2021;10(6):1182. https:\/\/doi.org\/10.3390\/jcm10061182.","journal-title":"J Clin Med"},{"key":"2208_CR45","first-page":"145","volume-title":"Bone sarcomas and bone metastases-from bench to bedside","author":"AM Cleton-Jansen","year":"2022","unstructured":"Cleton-Jansen AM. The role of mesenchymal stem cells in bone cancer: initiation, propagation, and metastasis. In: Bone sarcomas and bone metastases-from bench to bedside. Academic Press; 2022. p. 145\u201356."},{"issue":"2","key":"2208_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29442","volume":"69","author":"KM Ingley","year":"2022","unstructured":"Ingley KM, Maleddu A, Grange FL, Gerrand C, Bleyer A, Yasmin E, Whelan J, Strauss SJ. Current approaches to management of bone sarcoma in adolescent and young adult patients. Pediatr Blood Cancer. 2022;69(2): e29442. https:\/\/doi.org\/10.1002\/pbc.29442.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2208_CR47","first-page":"1181","volume":"24","author":"W Zhu","year":"2019","unstructured":"Zhu W, Zhu L, Bao Y, Zhong X, Chen Y, Wu Q. Clinical evaluation of neoadjuvant chemotherapy for osteosarcoma. J BUON. 2019;24(3):1181\u20135.","journal-title":"J BUON"},{"key":"2208_CR48","doi-asserted-by":"publisher","unstructured":"Jing S, Ding F, Yuan Y, An J, He Q. Efficacy of neoadjuvant chemotherapy plus limb-sparing surgery for osteosarcoma and its impact on long-term quality of life. Evidence-based complementary and alternative medicine: eCAM; 2022. 1693824. https:\/\/doi.org\/10.1155\/2022\/1693824 (Retraction published Evid Based Complement Alternat Med. 2023 Dec 6;2023:9850186. https:\/\/doi.org\/10.1155\/2023\/9850186)","DOI":"10.1155\/2022\/1693824"},{"issue":"16","key":"2208_CR49","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.3390\/cancers13164229","volume":"13","author":"AE B\u0103dil\u0103","year":"2021","unstructured":"B\u0103dil\u0103 AE, R\u0103dulescu DM, Niculescu AG, Grumezescu AM, R\u0103dulescu M, R\u0103dulescu AR. Recent advances in the treatment of bone metastases and primary bone tumors: an up-to-date review. Cancers. 2021;13(16):4229. https:\/\/doi.org\/10.3390\/cancers13164229.","journal-title":"Cancers"},{"key":"2208_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.873323","volume":"12","author":"K Yu","year":"2022","unstructured":"Yu K, Chen Y, Song K, Xiong F, Tian Y, Guan H, Li F. Impact of limb salvage on prognosis of patients diagnosed with extremity bone and soft tissue sarcomas. Front Oncol. 2022;12: 873323. https:\/\/doi.org\/10.3389\/fonc.2022.873323.","journal-title":"Front Oncol"},{"issue":"4","key":"2208_CR51","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.GOX.0000935128.68141.69","volume":"11","author":"A Polovneff","year":"2023","unstructured":"Polovneff A, Seitz V, Panoch J, Hoben G. D136. Spare the limb and spoil the outcome: why do some osteosarcoma patients pursue revision amputation and does the amputation improve the outcome. Plast Reconstr Surg Glob Open. 2023;11(4):126\u20137.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2208_CR52","doi-asserted-by":"publisher","first-page":"1147372","DOI":"10.3389\/fsurg.2023.1147372","volume":"10","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wu X, Zhang W, Zhang H. Limb-salvage surgery versus extremity amputation for early-stage bone cancer in the extremities: a population-based study. Front Surg. 2023;10:1147372. https:\/\/doi.org\/10.3389\/fsurg.2023.1147372.","journal-title":"Front Surg"},{"issue":"14","key":"2208_CR53","doi-asserted-by":"publisher","first-page":"11367","DOI":"10.3390\/ijms241411367","volume":"24","author":"BK Nirala","year":"2023","unstructured":"Nirala BK, Yamamichi T, Yustein JT. Deciphering the signaling mechanisms of osteosarcoma tumorigenesis. Int J Mol Sci. 2023;24(14):11367. https:\/\/doi.org\/10.3390\/ijms241411367.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2208_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12951-023-01826-1","volume":"21","author":"P Shi","year":"2023","unstructured":"Shi P, Cheng Z, Zhao K, Chen Y, Zhang A, Gan W, Zhang Y. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J Nanobiotechnol. 2023;21(1):103. https:\/\/doi.org\/10.1186\/s12951-023-01826-1.","journal-title":"J Nanobiotechnol"},{"key":"2208_CR55","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00086","author":"C Hu","year":"2019","unstructured":"Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.19.00086.","journal-title":"JCO Precis Oncol"},{"issue":"21","key":"2208_CR56","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/cells11213507","volume":"11","author":"Z Hu","year":"2022","unstructured":"Hu Z, Wen S, Huo Z, Wang Q, Zhao J, Wang Z, Chen Y, Zhang L, Zhou F, Guo Z, Liu H, Zhou S. Current status and prospects of targeted therapy for osteosarcoma. Cells. 2022;11(21):3507. https:\/\/doi.org\/10.3390\/cells11213507.","journal-title":"Cells"},{"issue":"4","key":"2208_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.308","volume":"4","author":"Z Ji","year":"2023","unstructured":"Ji Z, Shen J, Lan Y, Yi Q, Liu H. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. MedComm. 2023;4(4): e308. https:\/\/doi.org\/10.1002\/mco2.308.","journal-title":"MedComm"},{"key":"2208_CR58","doi-asserted-by":"publisher","first-page":"1030094","DOI":"10.3389\/fmed.2022.1030094","volume":"9","author":"PM Anderson","year":"2022","unstructured":"Anderson PM, Subbiah V, Trucco MM. Current and future targeted alpha particle therapies for osteosarcoma: radium-223, actinium-225, and thorium-227. Front Med. 2022;9:1030094. https:\/\/doi.org\/10.3389\/fmed.2022.1030094.","journal-title":"Front Med"},{"issue":"1","key":"2208_CR59","doi-asserted-by":"publisher","first-page":"15936","DOI":"10.1038\/ncomms15936","volume":"8","author":"S Behjati","year":"2017","unstructured":"Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun. 2017;8(1):15936. https:\/\/doi.org\/10.1038\/ncomms15936.","journal-title":"Nat Commun"},{"issue":"1","key":"2208_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s43046-024-00220-8","volume":"36","author":"H Kouchaki","year":"2024","unstructured":"Kouchaki H, Kamyab P, Darbeheshti F, Gharezade A, Fouladseresht H, Tabrizi R. miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review. J Egypt Natl Canc Inst. 2024;36(1):16. https:\/\/doi.org\/10.1186\/s43046-024-00220-8.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"5","key":"2208_CR61","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3892\/ijmm.2019.4333","volume":"44","author":"X Zhao","year":"2019","unstructured":"Zhao X, Li J, Yu D. MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K\/Akt pathway. Int J Mol Med. 2019;44(5):1833\u201343. https:\/\/doi.org\/10.3892\/ijmm.2019.4333. (Retraction published Int J Mol Med. 2022 Oct; 50(4):125. doi:10.3892\/ijmm.2022.5181)","journal-title":"Int J Mol Med"},{"issue":"5","key":"2208_CR62","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3892\/ijo.2018.4325","volume":"52","author":"YJ Chiu","year":"2018","unstructured":"Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Disruption of IGF-1R signaling by a novel quinazoline derivative, HMJ-30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U-2 OS cells. Int J Oncol. 2018;52(5):1465\u201378. https:\/\/doi.org\/10.3892\/ijo.2018.4325.","journal-title":"Int J Oncol"},{"issue":"2","key":"2208_CR63","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cjp2.191","volume":"7","author":"B Ameline","year":"2021","unstructured":"Ameline B, Kovac M, Nathrath M, Barenboim M, Witt O, Krieg AH, Baumhoer D. Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? J Pathol Clin Res. 2021;7(2):165\u201372. https:\/\/doi.org\/10.1002\/cjp2.191.","journal-title":"J Pathol Clin Res"},{"key":"2208_CR64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fendo.2015.00074","volume":"6","author":"C Garofalo","year":"2015","unstructured":"Garofalo C, Capristo M, Mancarella C, Reunevi H, Picci P, Scotlandi K. Preclinical Effectiveness of Selective Inhibitor of IRS-1\/2 NT157 in Osteosarcoma Cell Lines. Front Endocrinol. 2015;6:74. https:\/\/doi.org\/10.3389\/fendo.2015.00074.","journal-title":"Front Endocrinol"},{"issue":"2","key":"2208_CR65","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.4081\/ejh.2023.3612","volume":"67","author":"S Dong","year":"2023","unstructured":"Dong S, Xiao Y, Zhu Z, Ma X, Peng Z, Kang J, Wang J, Wang Y, Li Z. Metformin sensitises osteosarcoma to chemotherapy via the IGF-1R\/miR-610\/FEN1 pathway. Eur J Histochem EJH. 2023;67(2):3612. https:\/\/doi.org\/10.4081\/ejh.2023.3612.","journal-title":"Eur J Histochem EJH"},{"issue":"10","key":"2208_CR66","first-page":"3248","volume":"10","author":"D Cao","year":"2020","unstructured":"Cao D, Lei Y, Ye Z, Zhao L, Wang H, Zhang J, He F, Huang L, Shi D, Liu Q, Ni N, Pakvasa M, Wagstaff W, Zhao X, Fu K, Tucker AB, Chen C, Reid RR, Haydon RC, Luu HH, et al. Blockade of IGF\/IGF-1R signaling axis with soluble IGF-1R mutants suppresses the cell proliferation and tumor growth of human osteosarcoma. Am J Cancer Res. 2020;10(10):3248\u201366.","journal-title":"Am J Cancer Res"},{"key":"2208_CR67","doi-asserted-by":"publisher","first-page":"521","DOI":"10.18632\/oncotarget.28215","volume":"13","author":"ER Molina","year":"2022","unstructured":"Molina ER, Chim LK, Lamhamedi-Cherradi SE, Mohiuddin S, McCall D, Cuglievan B, Krishnan S, Porter RW, Ingram DR, Wang WL, Lazar AJ, Scott DW, Truong DD, Daw NC, Ludwig JA, Mikos AG. Correlation of nuclear pIGF-1R\/IGF-1R and YAP\/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget. 2022;13:521\u201333. https:\/\/doi.org\/10.18632\/oncotarget.28215.","journal-title":"Oncotarget"},{"issue":"16","key":"2208_CR68","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/cncr.28728","volume":"120","author":"AS Pappo","year":"2014","unstructured":"Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014;120(16):2448\u201356. https:\/\/doi.org\/10.1002\/cncr.28728.","journal-title":"Cancer"},{"issue":"11","key":"2208_CR69","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.18632\/aging.204117","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Zhou P, Lin L, Wu B, Fu Z, Huang X, Zhu D. Effective natural inhibitors targeting IGF-1R by computational study. Aging. 2022;14(11):4874\u201387. https:\/\/doi.org\/10.18632\/aging.204117.","journal-title":"Aging"},{"issue":"8_Supplement","key":"2208_CR70","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1538-7445.AM2023-LB329","volume":"83","author":"N Zhang","year":"2023","unstructured":"Zhang N, Dai C, Zhang J, Yang S, Wang J, Zhang J, et al. Abstract LB329: A potent and selective small molecule inhibitor of CSF-1R ABSK021 demonstrates strong efficacy in preclinical models of osteosarcoma. Cancer Res. 2023;83(8_Supplement):329\u2013329.","journal-title":"Cancer Res"},{"issue":"8","key":"2208_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29084","volume":"68","author":"MA Just","year":"2021","unstructured":"Just MA, Van Mater D, Wagner LM. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2021;68(8): e29084. https:\/\/doi.org\/10.1002\/pbc.29084.","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"2208_CR72","doi-asserted-by":"publisher","first-page":"15006","DOI":"10.3390\/ijms241915006","volume":"24","author":"MA Galal","year":"2023","unstructured":"Galal MA, Alouch SS, Alsultan BS, Dahman H, Alyabis NA, Alammar SA, Aljada A. Insulin receptor isoforms and insulin growth factor-like receptors: implications in cell signaling, carcinogenesis, and chemoresistance. Int J Mol Sci. 2023;24(19):15006. https:\/\/doi.org\/10.3390\/ijms241915006.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2208_CR73","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.3390\/ijms19113615","volume":"19","author":"V Vella","year":"2018","unstructured":"Vella V, Milluzzo A, Scalisi NM, Vigneri P, Sciacca L. Insulin receptor isoforms in cancer. Int J Mol Sci. 2018;19(11):3615. https:\/\/doi.org\/10.3390\/ijms19113615.","journal-title":"Int J Mol Sci"},{"key":"2208_CR74","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2019.02.037","volume":"450","author":"E Benabou","year":"2019","unstructured":"Benabou E, Salam\u00e9 Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chr\u00e9tien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C. Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem\/progenitor cell features. Cancer Lett. 2019;450:155\u201368. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.037.","journal-title":"Cancer Lett"},{"issue":"17","key":"2208_CR75","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-23-0709","volume":"29","author":"S Akshintala","year":"2023","unstructured":"Akshintala S, Sundby RT, Bernstein D, Glod JW, Kaplan RN, Yohe ME, Gross AM, Derdak J, Lei H, Pan A, Dombi E, Palacio-Yance I, Herrera KR, Miettinen MM, Chen HX, Steinberg SM, Helman LJ, Mascarenhas L, Widemann BC, Navid F, et al. Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma. Clin Cancer Res. 2023;29(17):3329\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0709.","journal-title":"Clin Cancer Res"},{"key":"2208_CR76","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.22.01815","volume":"41","author":"SG DuBois","year":"2023","unstructured":"DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, Chen HX, Seibel NL, Boron M, Terezakis S, et al. Randomized Phase III trial of ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2023;41:2098\u2013107.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2208_CR77","doi-asserted-by":"publisher","first-page":"15207","DOI":"10.1002\/cam4.6208","volume":"12","author":"DS Shulman","year":"2023","unstructured":"Shulman DS, Merriam P, Choy E, Guenther LM, Cavanaugh KL, Kao PC, Posner A, Bhushan K, Fairchild G, Barker E, Klega K, Stegmaier K, Crompton BD, London WB, DuBois SG. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023;12(14):15207\u201316. https:\/\/doi.org\/10.1002\/cam4.6208.","journal-title":"Cancer Med"},{"issue":"7","key":"2208_CR78","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/cancers12071768","volume":"12","author":"HM Amin","year":"2020","unstructured":"Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, et al. IGF-1R\/mTOR targeted therapy for ewing sarcoma: a meta-analysis of five IGF-1R-related trials matched to proteomic and radiologic predictive biomarkers. Cancers. 2020;12(7):1768. https:\/\/doi.org\/10.3390\/cancers12071768.","journal-title":"Cancers"},{"issue":"7","key":"2208_CR79","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1158\/1078-0432.CCR-14-0595","volume":"21","author":"M Fouladi","year":"2015","unstructured":"Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM. A phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: a children\u2019s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015;21(7):1558\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0595.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2208_CR80","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1200\/JCO.22.02430","volume":"41","author":"L Moreno","year":"2023","unstructured":"Moreno L, DuBois SG, Glade Bender J, Mauguen A, Bird N, Buenger V, Casanova M, Doz F, Fox E, Gore L, Hawkins DS, Izraeli S, Jones DTW, Kearns PR, Molenaar JJ, Nysom K, Pfister S, Reaman G, Smith M, Weigel B, et al. Combination early-phase trials of anticancer agents in children and adolescents. J Clin Oncol. 2023;41(18):3408\u201322. https:\/\/doi.org\/10.1200\/JCO.22.02430.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2208_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282512","volume":"18","author":"S Roche","year":"2023","unstructured":"Roche S, Gaule P, Winrow D, Mukherjee N, O\u2019Neill F, Conlon NT, Meiller J, Collins DM, Canonici A, Fawsi MI, Estepa-Fern\u00e1ndez A, Madden SF, Crown J, O\u2019Donovan N, Eustace AJ. Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. PLoS ONE. 2023;18(3): e0282512. https:\/\/doi.org\/10.1371\/journal.pone.0282512.","journal-title":"PLoS ONE"},{"issue":"17","key":"2208_CR82","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.3390\/cancers15174252","volume":"15","author":"J Guan","year":"2023","unstructured":"Guan J, Boren\u00e4s M, Xiong J, Lai WY, Palmer RH, Hallberg B. IGF1R contributes to cell proliferation in ALK-mutated neuroblastoma with preference for activating the PI3K-AKT signaling pathway. Cancers. 2023;15(17):4252. https:\/\/doi.org\/10.3390\/cancers15174252.","journal-title":"Cancers"},{"issue":"4","key":"2208_CR83","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cancers12040793","volume":"12","author":"O Beck","year":"2020","unstructured":"Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K, et al. Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma. Cancers. 2020;12(4):793. https:\/\/doi.org\/10.3390\/cancers12040793.","journal-title":"Cancers"},{"issue":"7","key":"2208_CR84","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/ph14070626","volume":"14","author":"J Bolcaen","year":"2021","unstructured":"Bolcaen J, Nair S, Driver CHS, Boshomane TMG, Ebenhan T, Vandevoorde C. Novel receptor tyrosine kinase pathway inhibitors for targeted radionuclide therapy of glioblastoma. Pharmaceuticals (Basel, Switzerland). 2021;14(7):626. https:\/\/doi.org\/10.3390\/ph14070626.","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"2208_CR85","doi-asserted-by":"publisher","first-page":"1148735","DOI":"10.3389\/fonc.2023.1148735","volume":"13","author":"B Shi","year":"2023","unstructured":"Shi B, Chang J, Sun X, Ma X, Zhao P, Zhou C, Wang Y, Yang Y. A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma. Front Oncol. 2023;13:1148735. https:\/\/doi.org\/10.3389\/fonc.2023.1148735.","journal-title":"Front Oncol"},{"issue":"1","key":"2208_CR86","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41420-022-01252-6","volume":"8","author":"C Chen","year":"2022","unstructured":"Chen C, Shi Q, Xu J, Ren T, Huang Y, Guo W. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma. Cell Death Discov. 2022;8(1):488. https:\/\/doi.org\/10.1038\/s41420-022-01252-6.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2208_CR87","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12645-022-00146-7","volume":"13","author":"F Giordano","year":"2022","unstructured":"Giordano F, Lenna S, Baudo G, Rampado R, Massaro M, De Rosa E, et al. Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma. Cancer Nanotechnol. 2022;13(1):40.","journal-title":"Cancer Nanotechnol"},{"issue":"5","key":"2208_CR88","doi-asserted-by":"publisher","first-page":"809","DOI":"10.7150\/jca.81623","volume":"14","author":"X Ding","year":"2023","unstructured":"Ding X, Zhang Y, Liang J, Li Q, Hu H, Zhou Y, Zhang B. Dihydroartemisinin potentiates VEGFR-TKIs antitumorigenic effect on osteosarcoma by regulating Loxl2\/VEGFA expression and lipid metabolism pathway. J Cancer. 2023;14(5):809\u201320. https:\/\/doi.org\/10.7150\/jca.81623.","journal-title":"J Cancer"},{"key":"2208_CR89","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3389\/fonc.2020.01642","volume":"10","author":"Z Tian","year":"2020","unstructured":"Tian Z, Niu X, Yao W. Receptor tyrosine kinases in osteosarcoma treatment: which is the key target? Front Oncol. 2020;10:1642. https:\/\/doi.org\/10.3389\/fonc.2020.01642.","journal-title":"Front Oncol"},{"key":"2208_CR90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e23540","author":"X Zhang","year":"2023","unstructured":"Zhang X, Pan Q, Peng R, Xu B, Hong D, Que Y. A phase II study of surufatinib in patients with osteosarcoma and soft tissue sarcoma who have experienced treatment failure with standard chemotherapy. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e23540.","journal-title":"J Clin Oncol"},{"key":"2208_CR91","doi-asserted-by":"publisher","first-page":"3691025","DOI":"10.1155\/2022\/3691025","volume":"2022","author":"P Frankel","year":"2022","unstructured":"Frankel P, Ruel C, Uche A, Choy E, Okuno S, Somiah N, Chow WA. Pazopanib in patients with osteosarcoma metastatic to the lung: phase 2 study results and the lessons for tumor measurement. J Oncol. 2022;2022:3691025. https:\/\/doi.org\/10.1155\/2022\/3691025.","journal-title":"J Oncol"},{"issue":"3","key":"2208_CR92","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/jayao.2021.0103","volume":"11","author":"V Avutu","year":"2022","unstructured":"Avutu V, Weiss AR, Reed DR, Ahmed SK, Allen-Rhoades WA, Chen YE, Davis LE, Eaton BR, Hawkins DS, Indelicato DJ, Patel SR, Randall RL, Reinke DK, Riedel RF, Scharschmidt TJ, Thornton KA, Wang D, Janeway KA, Kopp LM. Identified enrollment challenges of adolescent and young adult patients on the nonchemotherapy arm of children\u2019s oncology group study ARST1321. J Adolesc Young Adult Oncol. 2022;11(3):328\u201332. https:\/\/doi.org\/10.1089\/jayao.2021.0103.","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2208_CR93","doi-asserted-by":"publisher","first-page":"1013359","DOI":"10.3389\/fonc.2023.1013359","volume":"13","author":"EDG Fleuren","year":"2023","unstructured":"Fleuren EDG, Vlenterie M, van der Graaf WTA. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma. Front Oncol. 2023;13:1013359. https:\/\/doi.org\/10.3389\/fonc.2023.1013359.","journal-title":"Front Oncol"},{"issue":"6","key":"2208_CR94","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/cancers12061519","volume":"12","author":"G Chiabotto","year":"2020","unstructured":"Chiabotto G, Grignani G, Todorovic M, Martin V, Centomo ML, Prola E, Giordano G, Merlini A, Miglio U, Berrino E, Napione L, Isella C, Capozzi F, Basiric\u00f2 M, Marsero C, Gerardi I, Venesio T, Sangiolo D, Aglietta M, D\u2019Ambrosio L, et al. Pazopanib and trametinib as a synergistic strategy against osteosarcoma: preclinical activity and molecular insights. Cancers. 2020;12(6):1519. https:\/\/doi.org\/10.3390\/cancers12061519.","journal-title":"Cancers"},{"issue":"149","key":"2208_CR95","first-page":"8243","volume":"2023","author":"EC Unal","year":"2023","unstructured":"Unal EC, Incesoy Ozdemir S, Tacyildiz N, Dincaslan H, Dogrul C, Guven E, et al. Efficacy and safety of pazopanib in the treatment of pediatric sarcoma: retrospective cohort study. J Cancer Res Clin Oncol. 2023;2023(149):8243\u201353.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2208_CR96","doi-asserted-by":"publisher","first-page":"15963","DOI":"10.1038\/s41598-017-13114-8","volume":"7","author":"V Dembla","year":"2017","unstructured":"Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017;7(1):15963. https:\/\/doi.org\/10.1038\/s41598-017-13114-8.","journal-title":"Sci Rep"},{"issue":"2","key":"2208_CR97","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani G, Palmerini E, Dileo P, Asaftei SD, D\u2019Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508\u201316. https:\/\/doi.org\/10.1093\/annonc\/mdr151.","journal-title":"Ann Oncol"},{"issue":"1","key":"2208_CR98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","volume":"16","author":"G Grignani","year":"2015","unstructured":"Grignani G, Palmerini E, Ferraresi V, D\u2019Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M, Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(14)71136-2.","journal-title":"Lancet Oncol"},{"key":"2208_CR99","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","volume":"15","author":"Y Pignochino","year":"2015","unstructured":"Pignochino Y, Dell\u2019Aglio C, Inghilleri S, Zorzetto M, Basiric\u00f2 M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchi\u00f2 S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 2015;15:374. https:\/\/doi.org\/10.1186\/s12885-015-1363-1.","journal-title":"BMC Cancer"},{"issue":"5","key":"2208_CR100","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-023-04508-9","volume":"91","author":"R Varnier","year":"2023","unstructured":"Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. Cancer Chemother Pharmacol. 2023;91(5):361\u201373. https:\/\/doi.org\/10.1007\/s00280-023-04508-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2208_CR101","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.21873\/anticanres.13662","volume":"39","author":"T Higuchi","year":"2019","unstructured":"Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Kline Z, Belt P, Chawla SP, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. Combination treatment with sorafenib and everolimus regresses a doxorubicin-resistant osteosarcoma in a PDOX mouse model. Anticancer Res. 2019;39(9):4781\u20136. https:\/\/doi.org\/10.21873\/anticanres.13662.","journal-title":"Anticancer Res"},{"issue":"1","key":"2208_CR102","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2019","unstructured":"Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20(1):120\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30742-3.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2208_CR103","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3390\/cancers12123746","volume":"12","author":"T Brodowicz","year":"2020","unstructured":"Brodowicz T, Liegl-Atzwanger B, Penel N, Mir O, Blay JY, Kashofer K, Le Cesne A, Decoupigny E, Wallet J, Hamacher R, Deley ML. Assessing prognostic and predictive biomarkers of regorafenib response in patients with advanced soft tissue sarcoma: REGOSARC study. Cancers. 2020;12(12):3746. https:\/\/doi.org\/10.3390\/cancers12123746.","journal-title":"Cancers"},{"issue":"11","key":"2208_CR104","doi-asserted-by":"publisher","first-page":"e1655","DOI":"10.1634\/theoncologist.2020-0679","volume":"25","author":"RF Riedel","year":"2020","unstructured":"Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A randomized, double-blind, placebo-controlled, phase II study of regorafenib versus placebo in advanced\/metastatic, treatment-refractory liposarcoma: results from the SARC024 study. Oncologist. 2020;25(11):e1655\u201362. https:\/\/doi.org\/10.1634\/theoncologist.2020-0679.","journal-title":"Oncologist"},{"key":"2208_CR105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1158","author":"M Brahmi","year":"2022","unstructured":"Brahmi M, Gautier J, Dufresne A, Marec-Berard P, Cropet C, Vizoso S, Blay JY. REGOMAIN: a randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS1158.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2208_CR106","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.18.02374","volume":"37","author":"LE Davis","year":"2019","unstructured":"Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37(16):1424\u201331. https:\/\/doi.org\/10.1200\/JCO.18.02374.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2208_CR107","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/cam4.5044","volume":"12","author":"S Attia","year":"2023","unstructured":"Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 2023;12(2):1532\u20139. https:\/\/doi.org\/10.1002\/cam4.5044.","journal-title":"Cancer Med"},{"key":"2208_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100511","volume":"43","author":"A Assi","year":"2023","unstructured":"Assi A, Farhat M, Hachem MCR, Zalaquett Z, Aoun M, Daher M, Sebaaly A, Kourie HR. Tyrosine kinase inhibitors in osteosarcoma: adapting treatment strategiesa. J Bone Oncol. 2023;43: 100511. https:\/\/doi.org\/10.1016\/j.jbo.2023.100511.","journal-title":"J Bone Oncol"},{"key":"2208_CR109","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/CMAR.S353374","volume":"15","author":"N Hijiya","year":"2023","unstructured":"Hijiya N, Mauro MJ. Asciminib in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia: focus on patient selection and outcomes. Cancer Manag Res. 2023;15:873\u201391. https:\/\/doi.org\/10.2147\/CMAR.S353374.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"2208_CR110","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237\u201351. https:\/\/doi.org\/10.1038\/nrc3237.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2208_CR111","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s12885-024-12340-4","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Lin J, Wang R, Tong T, Zhao Y. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric\/gastroesophageal tumors: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):603. https:\/\/doi.org\/10.1186\/s12885-024-12340-4.","journal-title":"BMC Cancer"},{"issue":"5","key":"2208_CR112","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/ijms22052608","volume":"22","author":"R Ahn","year":"2021","unstructured":"Ahn R, Ursini-Siegel J. Clinical potential of kinase inhibitors in combination with immune checkpoint inhibitors for the treatment of solid tumors. Int J Mol Sci. 2021;22(5):2608. https:\/\/doi.org\/10.3390\/ijms22052608.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2208_CR113","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/hed.27018","volume":"44","author":"NL Michmerhuizen","year":"2022","unstructured":"Michmerhuizen NL, Ludwig ML, Birkeland AC, Nimmagadda S, Zhai J, Wang J, Jewell BM, Genouw D, Remer L, Kim D, Foltin SK, Bhangale A, Kulkarni A, Bradford CR, Swiecicki PL, Carey TE, Jiang H, Brenner JC. Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma. Head Neck. 2022;44(5):1192\u2013205. https:\/\/doi.org\/10.1002\/hed.27018.","journal-title":"Head Neck"},{"issue":"5","key":"2208_CR114","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1080\/21645515.2020.1824499","volume":"17","author":"K Yahiro","year":"2021","unstructured":"Yahiro K, Matsumoto Y. Immunotherapy for osteosarcoma. Hum Vaccin Immunother. 2021;17(5):1294\u20135. https:\/\/doi.org\/10.1080\/21645515.2020.1824499.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"2208_CR115","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3892\/ol.2015.3962","volume":"11","author":"J Wan","year":"2016","unstructured":"Wan J, Zhang X, Liu T, Zhang X. Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett. 2016;11(1):511\u201320. https:\/\/doi.org\/10.3892\/ol.2015.3962.","journal-title":"Oncol Lett"},{"issue":"2","key":"2208_CR116","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/ijms22020813","volume":"22","author":"I Fernandes","year":"2021","unstructured":"Fernandes I, Melo-Alvim C, Lopes-Br\u00e1s R, Esperan\u00e7a-Martins M, Costa L. Osteosarcoma pathogenesis leads the way to new target treatments. Int J Mol Sci. 2021;22(2):813. https:\/\/doi.org\/10.3390\/ijms22020813.","journal-title":"Int J Mol Sci"},{"key":"2208_CR117","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/B978-0-12-374895-9.00034-7","volume-title":"Bone cancer","author":"K Mori","year":"2010","unstructured":"Mori K, Ando K, Matsusue Y, Heymann D. Current status of immunotherapy for osteosarcoma and its future trends. In: Bone cancer. Academic Press; 2010. p. 417\u201325."},{"issue":"1","key":"2208_CR118","doi-asserted-by":"publisher","first-page":"32","DOI":"10.26502\/josm.511500076","volume":"5","author":"R Supra","year":"2023","unstructured":"Supra R, Agrawal DK. Immunotherapeutic Strategies in the Management of Osteosarcoma. J Orthopaed Sports Med. 2023;5(1):32\u201340. https:\/\/doi.org\/10.26502\/josm.511500076.","journal-title":"J Orthopaed Sports Med"},{"key":"2208_CR119","doi-asserted-by":"crossref","unstructured":"Bhattacharya P, Vadigepalli R. From tumor microenvironment to immuno-therapeutic outcomes for solid tumors: a systems theoretic approach. bioRxiv. 2024-09; 2024.","DOI":"10.1101\/2024.09.26.615155"},{"issue":"12","key":"2208_CR120","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3390\/cancers16122270","volume":"16","author":"AV Kuznetsova","year":"2024","unstructured":"Kuznetsova AV, Glukhova XA, Popova OP, Beletsky IP, Ivanov AA. Contemporary approaches to immunotherapy of solid tumors. Cancers. 2024;16(12):2270. https:\/\/doi.org\/10.3390\/cancers16122270.","journal-title":"Cancers"},{"issue":"1_Supplement","key":"2208_CR121","first-page":"230","volume":"210","author":"M Tanaka","year":"2023","unstructured":"Tanaka M, Lum L, Ledezma-Soto C, Hu K, Superville D, Adams Z, et al. An immunosuppressive tumor population drives immunotherapy resistance of heterogeneous tumors. J Immunol. 2023;210(1_Supplement):230\u2013304.","journal-title":"J Immunol"},{"issue":"6","key":"2208_CR122","doi-asserted-by":"publisher","first-page":"11","DOI":"10.55230\/mabjournal.v52i6.2413","volume":"52","author":"F Khamarudin","year":"2023","unstructured":"Khamarudin F, Muhamad M, Khan J, Ibahim MJ, Zain WNIWM, Aziz MA, et al. The interaction of immune system in tumour microenvironment and possible role of cancer cell immnunosensitization for better treatment efficacy: a review. Malay Appl Biol. 2023;52(6):11\u201321.","journal-title":"Malay Appl Biol"},{"key":"2208_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100675","volume":"20","author":"D Xiang","year":"2023","unstructured":"Xiang D, Han X, Li J, Zhang J, Xiao H, Li T, Zhao X, Xiong H, Xu M, Bi W. Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma. Mater Today Bio. 2023;20: 100675. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100675.","journal-title":"Mater Today Bio"},{"key":"2208_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.847621","volume":"10","author":"L Peng","year":"2022","unstructured":"Peng L, Fang H, Yang X, Zeng X. Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. Front Chem. 2022;10: 847621. https:\/\/doi.org\/10.3389\/fchem.2022.847621.","journal-title":"Front Chem"},{"issue":"4","key":"2208_CR125","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11914-023-00803-9","volume":"21","author":"I Panez-Toro","year":"2023","unstructured":"Panez-Toro I, Mu\u00f1oz-Garc\u00eda J, Vargas-Franco JW, Renodon-Corni\u00e8re A, Heymann MF, L\u00e9zot F, Heymann D. Advances in osteosarcoma. Curr Osteoporosis Rep. 2023;21(4):330\u201343. https:\/\/doi.org\/10.1007\/s11914-023-00803-9.","journal-title":"Curr Osteoporosis Rep"},{"key":"2208_CR126","doi-asserted-by":"publisher","first-page":"1031527","DOI":"10.3389\/fphar.2022.1031527","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Tan X, Jiang Z, Wang H, Yuan H. Immune checkpoint inhibitors in osteosarcoma: a hopeful and challenging future. Front Pharmacol. 2022;13:1031527. https:\/\/doi.org\/10.3389\/fphar.2022.1031527.","journal-title":"Front Pharmacol"},{"issue":"9","key":"2208_CR127","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","volume":"70","author":"K Boye","year":"2021","unstructured":"Boye K, Longhi A, Guren T, Lorenz S, N\u00e6ss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, L\u00f8ndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother CII. 2021;70(9):2617\u201324. https:\/\/doi.org\/10.1007\/s00262-021-02876-w.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"6","key":"2208_CR128","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","volume":"26","author":"EZ Keung","year":"2020","unstructured":"Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res. 2020;26(6):1258\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1824.","journal-title":"Clin Cancer Res"},{"key":"2208_CR129","doi-asserted-by":"crossref","unstructured":"Fillatre A, Marc-Antoine H, Pierre SG, Ahmed A, Audrey H. 5PSQ-014 safety and tolerance profile of nivolumab and pembrolizumab, A122.2\u2013A1A123; 2022.","DOI":"10.1136\/ejhpharm-2022-eahp.256"},{"issue":"23","key":"2208_CR130","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","volume":"27","author":"MB Livingston","year":"2021","unstructured":"Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, Foureau DM, Maxwell DM, Baldrige EA, Begic X, Symanowski JT, Steuerwald NM, Anderson CJ, Patt JC, Kneisl JS, Kim ES. Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma. Clin Cancer Res. 2021;27(23):6424\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2001.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2208_CR131","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","volume":"6","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, Trieselmann K, Copeland VC, Zhang S, Black G, McDonnell S, Gregory J, Johnson R, Moore R, Jones RL, Cranmer LD. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial. JAMA Oncol. 2020;6(11):1778\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3689.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2208_CR132","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","volume":"5","author":"R Groisberg","year":"2017","unstructured":"Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5(1):100. https:\/\/doi.org\/10.1186\/s40425-017-0301-y.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2208_CR133","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1078-0432.CCR-22-3911","volume":"29","author":"CM Kelly","year":"2023","unstructured":"Kelly CM, Qin LX, Whiting KA, Richards AL, Avutu V, Chan JE, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Adamson T, Singer S, Bartlett EK, Crago AM, Yoon SS, Hwang S, Erinjeri JP, et al. A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Clin Cancer Res. 2023;29(11):2043\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3911.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2208_CR134","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-018-0560-1","volume":"11","author":"B Zheng","year":"2018","unstructured":"Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11(1):16. https:\/\/doi.org\/10.1186\/s13045-018-0560-1.","journal-title":"J Hematol Oncol"},{"key":"2208_CR135","doi-asserted-by":"crossref","unstructured":"Reichardt P, Andreou D, Fl\u00f6rcken A, Gro\u00df T, Richter S, Kessler T et al. Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc); 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.11500"},{"issue":"4","key":"2208_CR136","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-22-2470","volume":"29","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Yang Q, Dong Y, Ji T, Zhang B, Yang C, Zheng S, Tang L, Zhou C, Qian G, Huang Y, Yu W, Li H, Wang Y, He A, Shen Z, Bao Q, Hua Y, Bai H, Zhao J, et al. First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I\/II trial of the anti-PD-L1 antibody ZKAB001. Clin Cancer Res. 2023;29(4):764\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2470.","journal-title":"Clin Cancer Res"},{"key":"2208_CR137","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S0959-8049(22)00841-3","volume":"174","author":"S Das","year":"2022","unstructured":"Das S, Dharani S, Valton J, Duchateau P, Poirot L. CAR-T cell engineering strategies aimed at safe and effective targeting of solid tumors. Eur J Cancer. 2022;174:S15.","journal-title":"Eur J Cancer"},{"issue":"18_Supplement","key":"2208_CR138","doi-asserted-by":"publisher","first-page":"A021","DOI":"10.1158\/1557-3265.SARCOMAS22-A021","volume":"28","author":"G Robbins","year":"2022","unstructured":"Robbins G, Yamomoto K, Lahr W, Skeate J. Abstract A021: chimeric antigen receptor armored natural killer cell immunotherapy for osteosarcoma. Clin Cancer Res. 2022;28(18_Supplement):A021\u2013A021.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2208_CR139","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00262-023-03437-z","volume":"72","author":"L Hidalgo","year":"2023","unstructured":"Hidalgo L, Somovilla-Crespo B, Garcia-Rodriguez P, Morales-Molina A, Rodriguez-Milla MA, Garcia-Castro J. Switchable CAR T cell strategy against osteosarcoma. Cancer Immunol Immunother CII. 2023;72(8):2623\u201333. https:\/\/doi.org\/10.1007\/s00262-023-03437-z.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"4","key":"2208_CR140","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ijlh.14121","volume":"45","author":"P Ramesh","year":"2023","unstructured":"Ramesh P, Hui HYL, Brownrigg LM, Fuller KA, Erber WN. Chimeric antigen receptor T-cells: Properties, production, and quality control. Int J Lab Hematol. 2023;45(4):425\u201335. https:\/\/doi.org\/10.1111\/ijlh.14121.","journal-title":"Int J Lab Hematol"},{"key":"2208_CR141","doi-asserted-by":"publisher","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030. https:\/\/doi.org\/10.3389\/fimmu.2023.1121030.","journal-title":"Front Immunol"},{"issue":"7_Supplement","key":"2208_CR142","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1158\/1538-7445.AM2023-1778","volume":"83","author":"AO Adeshakin","year":"2023","unstructured":"Adeshakin AO, Zhou P, M\u00e9tais JY, Nguyen P, Perry S, Sheppard H, et al. B7-H3-CAR T-cell therapy in immune-competent osteosarcoma models: Regnase-1 KO overcomes limited CAR T-cell expansion. Cancer Res. 2023;83(7_Supplement):1778\u20131778.","journal-title":"Cancer Res"},{"issue":"1","key":"2208_CR143","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","volume":"22","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhang Z, Liu G, Li D, Gu Z, Zhang L, Pan Y, Cui X, Wang L, Liu G, Tian X, Zhang Z. B7\u2013H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer. 2022;22(1):1124. https:\/\/doi.org\/10.1186\/s12885-022-10229-8.","journal-title":"BMC Cancer"},{"issue":"17","key":"2208_CR144","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-22-0721","volume":"28","author":"Q Yang","year":"2022","unstructured":"Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Membrane-anchored and tumor-targeted IL12 (attIL12)-PBMC therapy for osteosarcoma. Clin Cancer Res. 2022;28(17):3862\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0721.","journal-title":"Clin Cancer Res"},{"key":"2208_CR145","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/OTT.S341179","volume":"16","author":"J Maher","year":"2023","unstructured":"Maher J. Chimeric antigen receptor (CAR) T-cell therapy for patients with lung cancer: current perspectives. Onco Targets Ther. 2023;16:515\u201332. https:\/\/doi.org\/10.2147\/OTT.S341179.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"2208_CR146","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","volume":"7","author":"AQ Zhang","year":"2023","unstructured":"Zhang AQ, Hostetler A, Chen LE, Mukkamala V, Abraham W, Padilla LT, Wolff AN, Maiorino L, Backlund CM, Aung A, Melo M, Li N, Wu S, Irvine DJ. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat Biomed Eng. 2023;7(9):1113\u201328. https:\/\/doi.org\/10.1038\/s41551-023-01048-8.","journal-title":"Nat Biomed Eng"},{"key":"2208_CR147","doi-asserted-by":"publisher","first-page":"376","DOI":"10.54097\/hset.v36i.5706","volume":"36","author":"Q Li","year":"2023","unstructured":"Li Q, Wang K, Zhou J. Comprehensive overview of CAR-T cell therapy, engineering process and future prospects. Highlights Sci Eng Technol. 2023;36:376\u201384.","journal-title":"Highlights Sci Eng Technol"},{"issue":"11","key":"2208_CR148","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-21-0269","volume":"9","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Engineered T-cell receptor T cells for cancer immunotherapy. Cancer Immunol Res. 2021;9(11):1252\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0269.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2208_CR149","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/2326-6066.CIR-17-0434","volume":"6","author":"T Tsuji","year":"2018","unstructured":"Tsuji T, Yoneda A, Matsuzaki J, Miliotto A, Ryan C, Koya RC, Odunsi K. Rapid construction of antitumor T-cell receptor vectors from frozen tumors for engineered T-cell therapy. Cancer Immunol Res. 2018;6(5):594\u2013604. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0434.","journal-title":"Cancer Immunol Res"},{"key":"2208_CR150","doi-asserted-by":"crossref","unstructured":"Kok L, Eshuis S, Kroon P, Tubb V, Kong X, Linnemann C et al. 239 Engineering of potency-enhanced TCR-edited T cells for shared neoantigen-targeted cancer immunotherapy; 2022.","DOI":"10.1136\/jitc-2022-SITC2022.0239"},{"issue":"9","key":"2208_CR151","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3390\/cells10092379","volume":"10","author":"Y Sun","year":"2021","unstructured":"Sun Y, Li F, Sonnemann H, Jackson KR, Talukder AH, Katailiha AS, Lizee G. Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer. Cells. 2021;10(9):2379. https:\/\/doi.org\/10.3390\/cells10092379.","journal-title":"Cells"},{"issue":"74","key":"2208_CR152","doi-asserted-by":"publisher","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","volume":"7","author":"G Delfanti","year":"2022","unstructured":"Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, Garavaglia C, Squadrito ML, Fedeli M, Consonni M, Sesana S, Re F, Shen H, Dellabona P, Casorati G. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci Immunol. 2022;7(74):eabn6563. https:\/\/doi.org\/10.1126\/sciimmunol.abn6563.","journal-title":"Sci Immunol"},{"issue":"7_Supplement","key":"2208_CR153","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/1538-7445.AM2023-905","volume":"83","author":"J Grailer","year":"2023","unstructured":"Grailer J, Slater M, Hartnett J, Fan F, Cong M. A novel bioluminescent bioassay platform for the discovery and development of engineered T cell therapies for cancer. Cancer Res. 2023;83(7_Supplement):905\u2013905.","journal-title":"Cancer Res"},{"issue":"4","key":"2208_CR154","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/CJI.0000000000000456","volume":"46","author":"VE Anderson","year":"2023","unstructured":"Anderson VE, Brilha SS, Weber AM, Pachnio A, Wiedermann GE, Dauleh S, Ahmed T, Pope GR, Quinn LL, Docta RY, Quattrini A, Masters S, Cartwright N, Viswanathan P, Melchiori L, Rice LV, Sevko A, Gueguen C, Saini M, Tavano B, et al. Enhancing efficacy of TCR-engineered CD4+ T cells via coexpression of CD8\u03b1. J Immunother (Hagerstown, Md: 1997). 2023;46(4):132\u201344. https:\/\/doi.org\/10.1097\/CJI.0000000000000456.","journal-title":"J Immunother (Hagerstown, Md.: 1997)"},{"issue":"5_Supplement","key":"2208_CR155","doi-asserted-by":"publisher","first-page":"009","DOI":"10.1158\/1557-3125.RAS23-A009","volume":"21","author":"M Hoffmann","year":"2023","unstructured":"Hoffmann M, He X, Black C, Francis J, Parsons J, Roy C, et al. Abstract A009: AFNT-111: a novel TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V. Mol Cancer Res. 2023;21(5_Supplement):009\u2013009.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"2208_CR156","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700.","journal-title":"Sci Adv"},{"key":"2208_CR157","doi-asserted-by":"crossref","unstructured":"Choe M, Kirkey D, Ries RE, Hylkema T, Menashe SJ, Davis LE, et al. Preclinical testing of FOLR1-CAR T cells against osteosarcoma (OS). J Clin Oncol. 2023;41:2555\u20132555.","DOI":"10.1200\/JCO.2023.41.16_suppl.2555"},{"issue":"3\u20134","key":"2208_CR158","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","volume":"28","author":"K Hsu","year":"2021","unstructured":"Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021;28(3\u20134):321\u201334. https:\/\/doi.org\/10.1038\/s41417-020-00221-4.","journal-title":"Cancer Gene Ther"},{"issue":"12_Supplement","key":"2208_CR159","doi-asserted-by":"publisher","first-page":"CT142","DOI":"10.1158\/1538-7445.AM2022-CT142","volume":"82","author":"S Ramakrishna","year":"2022","unstructured":"Ramakrishna S, Kaczanowska S, Murty T, Contreras CF, Merchant M, Glod J, et al. Abstract CT142: GD2. Ox40. CD28. z CAR T cell trial in neuroblastoma and osteosarcoma. Cancer Res. 2022;82(12_Supplement):CT142-CR142.","journal-title":"Cancer Res"},{"issue":"1","key":"2208_CR160","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA, Baskar R, Wu CJ, Michor F, Altreuter J, Liu Y, Jhaveri A, Duong V, Anbunathan H, Ong C, Zhang H, Moravec R, Yu J, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024;42(1):35-51.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.011.","journal-title":"Cancer Cell"},{"issue":"19","key":"2208_CR161","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","volume":"23","author":"L Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez L, Metais JY, Escudero A, Vela M, Valent\u00edn J, Vallcorba I, Leivas A, Torres J, Valeri A, Pati\u00f1o-Garc\u00eda A, Mart\u00ednez J, Leung W, P\u00e9rez-Mart\u00ednez A. Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. Clin Cancer Res. 2017;23(19):5824\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0075.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2208_CR162","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41420-024-01976-7","volume":"10","author":"Y Deng","year":"2024","unstructured":"Deng Y, Kumar A, Xie K, Schaaf K, Scifo E, Morsy S, Li T, Ehninger A, Bano D, Ehninger D. Targeting senescent cells with NKG2D-CAR T cells. Cell Death Discov. 2024;10(1):217. https:\/\/doi.org\/10.1038\/s41420-024-01976-7.","journal-title":"Cell Death Discov"},{"key":"2208_CR163","doi-asserted-by":"publisher","first-page":"1391954","DOI":"10.3389\/fimmu.2024.1391954","volume":"15","author":"SJ Holzmayer","year":"2024","unstructured":"Holzmayer SJ, Liebel K, Hagelstein I, Salih HR, M\u00e4rklin M. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas. Front Immunol. 2024;15:1391954. https:\/\/doi.org\/10.3389\/fimmu.2024.1391954.","journal-title":"Front Immunol"},{"issue":"4","key":"2208_CR164","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends in cancer. 2024;10(4):312\u201331. https:\/\/doi.org\/10.1016\/j.trecan.2024.01.003.","journal-title":"Trends in cancer"},{"issue":"2","key":"2208_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28771","volume":"68","author":"KK Slemmons","year":"2021","unstructured":"Slemmons KK, Mukherjee S, Meltzer P, Purcell JW, Helman LJ. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr Blood Cancer. 2021;68(2): e28771. https:\/\/doi.org\/10.1002\/pbc.28771.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2208_CR166","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/1535-7163.MCT-20-0406","volume":"20","author":"P Hingorani","year":"2021","unstructured":"Hingorani P, Roth ME, Wang Y, Zhang W, Gill JB, Harrison DJ, Teicher B, Erickson S, Gatto G, Smith MA, Kolb EA, Gorlick R. ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: a report by the pediatric preclinical testing consortium. Mol Cancer Ther. 2021;20(3):535\u201340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0406.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2208_CR167","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1158\/0008-5472.CAN-21-3734","volume":"82","author":"U Ray","year":"2022","unstructured":"Ray U, Pathoulas CL, Thirusangu P, Purcell JW, Kannan N, Shridhar V. Exploiting LRRC15 as a novel therapeutic target in cancer. Can Res. 2022;82(9):1675\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3734.","journal-title":"Can Res"},{"issue":"13","key":"2208_CR168","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri GD, Luke JJ, Hollebecque A, Powderly JD 2nd, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher A, Villalobos VM. First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin Cancer Res. 2021;27(13):3556\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4513.","journal-title":"Clin Cancer Res"},{"issue":"7_Supplement","key":"2208_CR169","doi-asserted-by":"publisher","first-page":"LB402","DOI":"10.1158\/1538-7445.AM2024-LB402","volume":"84","author":"R Gorlick","year":"2024","unstructured":"Gorlick R, Gill J, Zhang W, Mosse Y, Maris J, Groff D, et al. Abstract LB402: in vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): an update from the pediatric preclinical in vivo testing (PIVOT) Program. Cancer Res. 2024;84(7_Supplement):LB402.","journal-title":"Cancer Res"},{"issue":"12_Supplement","key":"2208_CR170","doi-asserted-by":"publisher","first-page":"LB061","DOI":"10.1158\/1538-7445.AM2022-LB061","volume":"82","author":"R Gorlick","year":"2022","unstructured":"Gorlick R, Kolb EA, Wang Y, Houghton P, Kurmasheva R, Mosse Y, et al. Abstract LB061: evaluation of the in vivo efficacy of the B7\u2013H3 targeting antibody-drug conjugate (ADC) DS7300a: a report for the pediatric preclinical in vivo resting (PIVOT) program. Cancer Res. 2022;82(12_Supplement):LB061.","journal-title":"Cancer Res"},{"key":"2208_CR171","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.10037","author":"R Kurmasheva","year":"2021","unstructured":"Kurmasheva R, Mosse YP, Del Pozo V, Earley EJ, Erickson SW, Groff D, et al. Testing of B7\u2013H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC). J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.10037.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2208_CR172","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.3390\/molecules28083356","volume":"28","author":"P Rasic","year":"2023","unstructured":"Rasic P, Jeremic M, Jeremic R, Dusanovic Pjevic M, Rasic M, Djuricic SM, et al. Targeting B7\u2013H3\u2014a novel strategy for the design of anticancer agents for extracranial pediatric solid tumors treatment. Molecules. 2023;28(8):3356. https:\/\/doi.org\/10.3390\/molecules28083356.","journal-title":"Molecules"},{"issue":"3","key":"2208_CR173","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00438-023-02010-8","volume":"298","author":"SF Pires","year":"2023","unstructured":"Pires SF, de Barros JS, da Costa SS, de Oliveira Scliar M, Van Helvoort Lengert A, Boldrini \u00c9, da Silva SRM, Tasic L, Vidal DO, Krepischi ACV, Maschietto M. DNA methylation patterns suggest the involvement of DNMT3B and TET1 in osteosarcoma development. Mol Genet Genomics MGG. 2023;298(3):721\u201333. https:\/\/doi.org\/10.1007\/s00438-023-02010-8.","journal-title":"Mol Genet Genomics MGG"},{"issue":"5","key":"2208_CR174","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.3390\/ijms24054539","volume":"24","author":"M Bereza","year":"2023","unstructured":"Bereza M, Dembi\u0144ski M, Zaj\u0105c AE, Pi\u0105tkowski J, Dudzisz-\u015aled\u017a M, Rutkowski P, Czarnecka AM. Epigenetic Abnormalities in chondrosarcoma. Int J Mol Sci. 2023;24(5):4539. https:\/\/doi.org\/10.3390\/ijms24054539.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2208_CR175","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/cells12121595","volume":"12","author":"L Twenhafel","year":"2023","unstructured":"Twenhafel L, Moreno D, Punt T, Kinney M, Ryznar R. Epigenetic changes associated with osteosarcoma: a comprehensive review. Cells. 2023;12(12):1595. https:\/\/doi.org\/10.3390\/cells12121595.","journal-title":"Cells"},{"key":"2208_CR176","doi-asserted-by":"publisher","first-page":"153303382412503","DOI":"10.1177\/15330338241250317","volume":"23","author":"F Akram","year":"2024","unstructured":"Akram F, Tanveer R, Andleeb S, Shah FI, Ahmad T, Shehzadi S, Akhtar AM, Syed G. Deciphering the epigenetic symphony of cancer: insights and epigenetic therapies implications. Technol Cancer Res Treat. 2024;23:15330338241250316. https:\/\/doi.org\/10.1177\/15330338241250317.","journal-title":"Technol Cancer Res Treat"},{"key":"2208_CR177","doi-asserted-by":"publisher","first-page":"2719172","DOI":"10.1155\/2021\/2719172","volume":"2021","author":"S Liu","year":"2021","unstructured":"Liu S, Wu B, Li X, Zhao L, Wu W, Ai S. Construction and validation of a potent epigenetic modification-related prognostic signature for osteosarcoma patients. J Oncol. 2021;2021:2719172. https:\/\/doi.org\/10.1155\/2021\/2719172.","journal-title":"J Oncol"},{"key":"2208_CR178","doi-asserted-by":"publisher","first-page":"7596122","DOI":"10.1155\/2022\/7596122","volume":"2022","author":"Y Kang","year":"2022","unstructured":"Kang Y, Li G, Wang G, Huo Z, Feng X, Du L, Li Y, Yang Q, Ma X, Yu B, Xu B. Development of a risk score model for osteosarcoma based on DNA methylation-driven differentially expressed genes. J Oncol. 2022;2022:7596122. https:\/\/doi.org\/10.1155\/2022\/7596122.","journal-title":"J Oncol"},{"key":"2208_CR179","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jbo.2017.05.001","volume":"9","author":"J Xu","year":"2017","unstructured":"Xu J, Li D, Cai Z, Zhang Y, Huang Y, Su B, Ma R. An integrative analysis of DNA methylation in osteosarcoma. J Bone Oncol. 2017;9:34\u201340. https:\/\/doi.org\/10.1016\/j.jbo.2017.05.001.","journal-title":"J Bone Oncol"},{"key":"2208_CR180","doi-asserted-by":"publisher","first-page":"1610047","DOI":"10.3389\/pore.2022.1610047","volume":"28","author":"B Wang","year":"2022","unstructured":"Wang B, Sun Y. SELPLG expression was potentially correlated with metastasis and prognosis of osteosarcoma. Pathol Oncol Res POR. 2022;28:1610047. https:\/\/doi.org\/10.3389\/pore.2022.1610047.","journal-title":"Pathol Oncol Res POR"},{"issue":"1","key":"2208_CR181","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41392-023-01528-y","volume":"8","author":"R Liu","year":"2023","unstructured":"Liu R, Zhao E, Yu H, Yuan C, Abbas MN, Cui H. Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduct Target Ther. 2023;8(1):310. https:\/\/doi.org\/10.1038\/s41392-023-01528-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2208_CR182","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/1535-7163.MCT-17-0818","volume":"17","author":"MC Manara","year":"2018","unstructured":"Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K. A Quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy. Mol Cancer Ther. 2018;17(9):1881\u201392. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0818.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2208_CR183","doi-asserted-by":"publisher","first-page":"zcad022","DOI":"10.1093\/narcan\/zcad022","volume":"5","author":"Q Chen","year":"2023","unstructured":"Chen Q, Liu B, Zeng Y, Hwang JW, Dai N, Corr\u00eaa IR Jr, Estecio MR, Zhang X, Santos MA, Chen T, Cheng X. GSK-3484862 targets DNMT1 for degradation in cells. NAR cancer. 2023;5(2):zcad022. https:\/\/doi.org\/10.1093\/narcan\/zcad022.","journal-title":"NAR cancer"},{"issue":"1","key":"2208_CR184","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1038\/s41598-021-82539-z","volume":"11","author":"JA Halsall","year":"2021","unstructured":"Halsall JA, Andrews S, Krueger F, Rutledge CE, Ficz G, Reik W, Turner BM. Histone modifications form a cell-type-specific chromosomal bar code that persists through the cell cycle. Sci Rep. 2021;11(1):3009. https:\/\/doi.org\/10.1038\/s41598-021-82539-z.","journal-title":"Sci Rep"},{"issue":"11","key":"2208_CR185","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1093\/nar\/gkab280","volume":"49","author":"HY Ryu","year":"2021","unstructured":"Ryu HY, Hochstrasser M. Histone sumoylation and chromatin dynamics. Nucleic Acids Res. 2021;49(11):6043\u201352. https:\/\/doi.org\/10.1093\/nar\/gkab280.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2208_CR186","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/290368","volume":"2015","author":"X Mu","year":"2015","unstructured":"Mu X, Brynien D, Weiss KR. The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of osteosarcoma cells. Biomed Res Int. 2015;2015(1): 290368. https:\/\/doi.org\/10.1155\/2015\/290368.","journal-title":"Biomed Res Int"},{"issue":"7","key":"2208_CR187","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/era.10.88","volume":"10","author":"C Grant","year":"2010","unstructured":"Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997\u20131008. https:\/\/doi.org\/10.1586\/era.10.88.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2208_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114774","volume":"164","author":"N El Omari","year":"2023","unstructured":"El Omari N, Lee LH, Bakrim S, Makeen HA, Alhazmi HA, Mohan S, et al. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin. Biomed Pharmacother. 2023;164: 114774. https:\/\/doi.org\/10.1016\/j.biopha.2023.114774.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2208_CR189","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1038\/bcj.2015.83","volume":"5","author":"BC Valdez","year":"2015","unstructured":"Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5(10):e357\u2013e357. https:\/\/doi.org\/10.1038\/bcj.2015.83.","journal-title":"Blood Cancer J"},{"issue":"10","key":"2208_CR190","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1002\/ijc.33046","volume":"147","author":"JJ McGuire","year":"2020","unstructured":"McGuire JJ, Nerlakanti N, Lo CH, Tauro M, Utset-Ward TJ, Reed DR, Lynch CC. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma. Int J Cancer. 2020;147(10):2811\u201323. https:\/\/doi.org\/10.1002\/ijc.33046.","journal-title":"Int J Cancer"},{"issue":"1","key":"2208_CR191","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12885-017-3046-6","volume":"17","author":"S Murahari","year":"2017","unstructured":"Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer. 2017;17(1):67. https:\/\/doi.org\/10.1186\/s12885-017-3046-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"2208_CR192","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13046-018-0978-x","volume":"37","author":"M La Noce","year":"2018","unstructured":"La Noce M, Paino F, Mele L, Papaccio G, Regad T, Lombardi A, Papaccio F, Desiderio V, Tirino V. HDAC2 depletion promotes osteosarcoma\u2019s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. J Exp Clin Cancer Res CR. 2018;37(1):296. https:\/\/doi.org\/10.1186\/s13046-018-0978-x.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"2208_CR193","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-030-43032-0_7","volume":"1257","author":"S Kiany","year":"2020","unstructured":"Kiany S, Harrison D, Gordon N. The Histone Deacetylase Inhibitor Entinostat\/Syndax 275 in Osteosarcoma. Adv Exp Med Biol. 2020;1257:75\u201383. https:\/\/doi.org\/10.1007\/978-3-030-43032-0_7.","journal-title":"Adv Exp Med Biol"},{"key":"2208_CR194","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/B:APPT.0000038037.68908.6e","volume":"9","author":"MS Roh","year":"2004","unstructured":"Roh MS, Kim CW, Park BS, Kim GC, Jeong JH, Kwon HC, et al. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis. 2004;9:583\u20139. https:\/\/doi.org\/10.1023\/B:APPT.0000038037.68908.6e.","journal-title":"Apoptosis"},{"key":"2208_CR195","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105418","author":"C Xie","year":"2016","unstructured":"Xie C, Wu B, Chen B, Shi Q, Guo J, Fan Z, Huang Y. Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2\u2013p53 signaling. OncoTargets Ther. 2016. https:\/\/doi.org\/10.2147\/OTT.S105418.","journal-title":"OncoTargets Ther"},{"key":"2208_CR196","first-page":"1032","volume":"18","author":"Z Wu","year":"2013","unstructured":"Wu Z, Ma C, Shan Z, Ju Y, Li S, Zhao Q. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo. J BUON. 2013;18:1032\u20137.","journal-title":"J BUON"},{"issue":"8","key":"2208_CR197","doi-asserted-by":"publisher","first-page":"BSR20210952","DOI":"10.1042\/BSR20210952","volume":"41","author":"CM Sergi","year":"2021","unstructured":"Sergi CM. Targeting the \u2018garbage-bin\u2019 to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU. Biosci Rep. 2021;41(8):BSR20210952. https:\/\/doi.org\/10.1042\/BSR20210952.","journal-title":"Biosci Rep"},{"issue":"11","key":"2208_CR198","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1158\/0008-5472.CAN-15-2249","volume":"76","author":"R Pathania","year":"2016","unstructured":"Pathania R, Ramachandran S, Mariappan G, Thakur P, Shi H, Choi JH, Manicassamy S, Kolhe R, Prasad PD, Sharma S, Lokeshwar BL, Ganapathy V, Thangaraju M. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Can Res. 2016;76(11):3224\u201335. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2249.","journal-title":"Can Res"},{"issue":"22","key":"2208_CR199","doi-asserted-by":"publisher","first-page":"16488","DOI":"10.3390\/ijms242216488","volume":"24","author":"PR Manna","year":"2023","unstructured":"Manna PR, Yang S, Reddy PH. Epigenetic dysregulation and its correlation with the steroidogenic machinery impacting breast pathogenesis: data mining and molecular insights into therapeutics. Int J Mol Sci. 2023;24(22):16488. https:\/\/doi.org\/10.3390\/ijms242216488.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2208_CR200","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1):31. https:\/\/doi.org\/10.1186\/s13045-024-01544-7.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2208_CR201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095596","volume":"9","author":"E Capobianco","year":"2014","unstructured":"Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, Badidi E, et al. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS ONE. 2014;9(4): e95596. https:\/\/doi.org\/10.1371\/journal.pone.0095596.","journal-title":"PLoS ONE"},{"issue":"1","key":"2208_CR202","doi-asserted-by":"publisher","first-page":"16991","DOI":"10.1038\/srep16991","volume":"5","author":"D Yu","year":"2015","unstructured":"Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, et al. Identification of synergistic, clinically achievable, combination therapies for osteosarcoma. Sci Rep. 2015;5(1):16991. https:\/\/doi.org\/10.1038\/srep16991.","journal-title":"Sci Rep"},{"issue":"1","key":"2208_CR203","doi-asserted-by":"publisher","first-page":"20360","DOI":"10.1038\/s41598-019-56883-0","volume":"9","author":"N Asano","year":"2019","unstructured":"Asano N, Takeshima H, Yamashita S, Takamatsu H, Hattori N, Kubo T, Yoshida A, Kobayashi E, Nakayama R, Matsumoto M, Nakamura M, Ichikawa H, Kawai A, Kondo T, Ushijima T. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. Sci Rep. 2019;9(1):20360. https:\/\/doi.org\/10.1038\/s41598-019-56883-0.","journal-title":"Sci Rep"},{"key":"2208_CR204","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.2147\/OTT.S200643","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang J, Pang Y, Xie T, Zhu L. CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases. Onco Targets Ther. 2019;12:4985\u201392. https:\/\/doi.org\/10.2147\/OTT.S200643.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"2208_CR205","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, Yan H, Tian Y, Wang Z, Yang Z, Yang S, Yang Y, Wang Q. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19(11):3341\u201359. https:\/\/doi.org\/10.7150\/ijbs.82317.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2208_CR206","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/1535-7163.MCT-21-0565","volume":"21","author":"N Martinez-Velez","year":"2022","unstructured":"Martinez-Velez N, Laspidea V, Zalacain M, Labiano S, Garc\u00eda-Moure M, Puigdelloses M, Marrodan L, Gonzalez-Huarriz M, Herrador G, de la Nava D, Ausejo-Mauleon I, Fueyo J, Gomez-Manzano C, Pati\u00f1o-Garc\u00eda A, Alonso MM. Local treatment of a pediatric osteosarcoma model with a 4\u20131BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memory. Mol Cancer Ther. 2022;21(3):471\u201380. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0565.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2208_CR207","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00280-021-04310-5","volume":"88","author":"K Sugiu","year":"2021","unstructured":"Sugiu K, Tazawa H, Hasei J, Yamakawa Y, Omori T, Komatsubara T, Mochizuki Y, Kondo H, Osaki S, Fujiwara T, Yoshida A, Kunisada T, Ueda K, Urata Y, Kagawa S, Ozaki T, Fujiwara T. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression. Cancer Chemother Pharmacol. 2021;88(3):513\u201324. https:\/\/doi.org\/10.1007\/s00280-021-04310-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2208_CR208","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"CC Wu","year":"2020","unstructured":"Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11(1):1008. https:\/\/doi.org\/10.1038\/s41467-020-14646-w.","journal-title":"Nat Commun"},{"key":"2208_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103980","volume":"185","author":"M Ajam-Hosseini","year":"2023","unstructured":"Ajam-Hosseini M, Akhoondi F, Doroudian M. Nano based-oncolytic viruses for cancer therapy. Crit Rev Oncol Hematol. 2023;185: 103980. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103980.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2208_CR210","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/cancers12020478","volume":"12","author":"H Tazawa","year":"2020","unstructured":"Tazawa H, Hasei J, Yano S, Kagawa S, Ozaki T, Fujiwara T. Bone and soft-tissue sarcoma: a new target for telomerase-specific oncolytic virotherapy. Cancers. 2020;12(2):478. https:\/\/doi.org\/10.3390\/cancers12020478.","journal-title":"Cancers"},{"issue":"2","key":"2208_CR211","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40291-023-00689-4","volume":"28","author":"GM Stergiopoulos","year":"2024","unstructured":"Stergiopoulos GM, Iankov I, Galanis E. Personalizing oncolytic immunovirotherapy approaches. Mol Diagn Ther. 2024;28(2):153\u201368. https:\/\/doi.org\/10.1007\/s40291-023-00689-4.","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"2208_CR212","doi-asserted-by":"publisher","first-page":"151","DOI":"10.18926\/AMO\/66924","volume":"78","author":"T Komatsubara","year":"2024","unstructured":"Komatsubara T, Tazawa H, Hasei J, Omori T, Sugiu K, Mochizuki Y, Demiya K, Yoshida A, Fujiwara T, Kunisada T, Urata Y, Kagawa S, Ozaki T, Fujiwara T. p53-armed oncolytic virotherapy improves radiosensitivity in soft-tissue sarcoma by suppressing BCL-xL expression. Acta Med Okayama. 2024;78(2):151\u201361. https:\/\/doi.org\/10.18926\/AMO\/66924.","journal-title":"Acta Med Okayama"},{"issue":"5","key":"2208_CR213","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","volume":"72","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara Y, Tazawa H, Yamada M, Kanaya N, Fushimi T, Kikuchi S, Kuroda S, Ohara T, Noma K, Yoshida R, Umeda Y, Urata Y, Kagawa S, Fujiwara T. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol Immunother CII. 2023;72(5):1285\u2013300. https:\/\/doi.org\/10.1007\/s00262-022-03334-x.","journal-title":"Cancer Immunol Immunother CII"},{"key":"2208_CR214","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-030-43085-6_5","volume":"1258","author":"MF Wedekind","year":"2020","unstructured":"Wedekind MF, Cripe TP. Oncolytic viruses and their potential as a therapeutic opportunity in osteosarcoma. Adv Exp Med Biol. 2020;1258:77\u201389. https:\/\/doi.org\/10.1007\/978-3-030-43085-6_5.","journal-title":"Adv Exp Med Biol"},{"issue":"18_Supplement","key":"2208_CR215","doi-asserted-by":"publisher","first-page":"A030","DOI":"10.1158\/1557-3265.sarcomas22-a030","volume":"28","author":"AN Hay","year":"2022","unstructured":"Hay AN, Ruger L, Hixson H, Gannon J, Simon A, Sheppard H, Coutermarsh-Ott S, Davis E, Kierski K, Ciepluch B, Neufeld N. Abstract A030: investigating the feasibility of in-vivo histotripsy ablation for osteosarcoma using an orthotopic murine model and a canine model of spontaneous disease. Clin Cancer Res. 2022;28(18_Supplement):A030\u2013A030. https:\/\/doi.org\/10.1158\/1557-3265.sarcomas22-a030.","journal-title":"Clin Cancer Res"},{"key":"2208_CR216","doi-asserted-by":"publisher","unstructured":"Makielski KM, Sarver AL, Henson MS, Stuebner K, Borgatti A, Suksanpaisan L, Ta\u0306ba\u0306ran AF, Cornax I, O\u2019Sullivan MG, Chehadeh A, Groschen DM, Bergsrud K, Pracht S, Winter AL, Mills LJ, Schwabenlander M, Farrar MA, Cutter G, Koopmeiners JS, Russell SJ, Modiano JF, Naik S. Oncolytic vesicular stomatitis virus is safe and provides a survival benefit for dogs with naturally occurring osteosarcoma. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.04.16.533664","DOI":"10.1101\/2023.04.16.533664"},{"issue":"1","key":"2208_CR217","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/s41598-023-50340-9","volume":"14","author":"L Chow","year":"2024","unstructured":"Chow L, Wheat W, Ramirez D, Impastato R, Dow S. Direct comparison of canine and human immune responses using transcriptomic and functional analyses. Sci Rep. 2024;14(1):2207. https:\/\/doi.org\/10.1038\/s41598-023-50340-9.","journal-title":"Sci Rep"},{"issue":"7_Supplement","key":"2208_CR218","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/1538-7445.AM2023-2339","volume":"83","author":"AA Ismail","year":"2023","unstructured":"Ismail AA, Patton DJ, Higgins TA, Sandey M, Smith BF, Agarwal P. Exploration of multiple immunotherapy modalities in ostesarcoma. Cancer Res. 2023;83(7_Supplement):2339\u20132339.","journal-title":"Cancer Res"},{"issue":"6_Supplement","key":"2208_CR219","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1538-7445.AM2024-1087","volume":"84","author":"E Ringwalt","year":"2024","unstructured":"Ringwalt E, Currier M, Glaspell A, Cannon MV, Chen CY, Gross AC, et al. Synergistic mechanisms against pediatric bone sarcoma models: trabectedin enhances oncolytic virotherapy intratumoral spread and antitumor immune activation. Cancer Res. 2024;84(6_Supplement):1087\u20131087.","journal-title":"Cancer Res"},{"key":"2208_CR220","doi-asserted-by":"publisher","first-page":"657","DOI":"10.54097\/avck7547","volume":"74","author":"X Zhang","year":"2023","unstructured":"Zhang X. Clinical challenges and strategies on delivery of oncolytic virus. Highlights Sci Eng Technol. 2023;74:657\u201363.","journal-title":"Highlights Sci Eng Technol"},{"issue":"17_Supplement","key":"2208_CR221","doi-asserted-by":"publisher","first-page":"B049","DOI":"10.1158\/1538-7445.PEDIATRIC24-B049","volume":"84","author":"TK Barr","year":"2024","unstructured":"Barr TK, Jennings VA, Taylor A, Murby J, Caplen NJ, Khan J, et al. Abstract B049: Oncolytic HSV1716-GMCSF combination strategies to remodel the immunosuppressive osteosarcoma tumor-microenvironment and promote anti-tumor immunity. Cancer Res. 2024;84(17_Supplement):B049\u2013B049.","journal-title":"Cancer Res"},{"key":"2208_CR222","doi-asserted-by":"publisher","first-page":"1082797","DOI":"10.3389\/fphar.2022.1082797","volume":"13","author":"RK Omole","year":"2022","unstructured":"Omole RK, Oluwatola O, Akere MT, Eniafe J, Agboluaje EO, Daramola OB, et al. Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. Front Pharmacol. 2022;13:1082797. https:\/\/doi.org\/10.3389\/fphar.2022.1082797.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2208_CR223","doi-asserted-by":"publisher","first-page":"164","DOI":"10.36266\/JBSR\/164","volume":"4","author":"X Wang","year":"2022","unstructured":"Wang X, Maeng HM, Lee J, Xie C. Therapeutic implementation of oncolytic viruses for cancer immunotherapy: review of challenges and current clinical trials. J Biomed Sci Res. 2022;4(2):164. https:\/\/doi.org\/10.36266\/JBSR\/164.","journal-title":"J Biomed Sci Res"},{"issue":"1","key":"2208_CR224","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"2208_CR225","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202206948","volume":"19","author":"S Duan","year":"2023","unstructured":"Duan S, Wang S, Qiao L, Yu X, Wang N, Chen L, Zhang X, Zhao X, Liu H, Wang T, Wu Y, Li N, Liu F. Oncolytic virus-driven biotherapies from bench to bedside. Small. 2023;19(23): e2206948. https:\/\/doi.org\/10.1002\/smll.202206948.","journal-title":"Small"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02208-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:17:30Z","timestamp":1757254650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":225,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02208-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (review paper).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1367"}}